Pfizer’s oncology strategy and vision sounds like an invitation for ”the ride of your life”!

Pfizer’s oncology strategy and vision sounds like an invitation for ”the ride of your life”!

There are times when we are grateful to be given just a wee snippet of what’s important in the minds of our leaders.  And then….there are times when the floodgates open and our leaders tell us what is really keeping them up at night and what they hope to achieve.  They’re saying, ”Join us for the ride of your life!”  And that is exactly what the top brass at Pfizer did on their Pfizer Oncology Innovation Day last Thursday the 29th February 2024.

Terrific vision to accelerate the next generation of cancer drugs.  Pfizer aims to have at least 8 oncology blockbusters by 2030.  So, where are the specific priorities?  There are 3.  Firstly, small molecules will continue to be an active approach.   Then,  Antibody Drug Conjugates or ADCs is definitely going to be a BIG player.  Remember that barely 2 months ago in December 2023, Pfizer paid $43m to acquire Seagen, a top ADC player.  And getting more ADCs out is what they are going to do for that money.  Then thirdly, the immuno-oncology bispecifics is just gaining pace, so that looks like it’s going to accelerate even more.  And we also know where Pfizer is going to focus on in terms of organ location – there are 4:  Breast, Genitourinary, Hematology and Thoracic.  It’s a nice document and it’s definitely worth a read.  Give it a go!

READ THE ARTICLE – https://investors.pfizer.com/Investors/Events–Presentations/event-details/2024/Pfizer-Oncology-Innovation-Day-2024-oiNd1QeCMl/default.aspx

Share this post